Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Tirzepatide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention. Browse Tirzepatide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
178
Shown on this page
12
Current sort
Recently updated
Therapy scope
Tirzepatide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Tirzepatide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 61–72 of 178 matching trials for Tirzepatide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Not applicable Interventional Accepts healthy volunteers

Tirzepatide Impact Assessment Study

NCT07740291
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
Interventions
GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
Drug · Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Recruiting Phase 2 Interventional

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

NCT07573163
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
Interventions
Tirzepatide, Standard medical treatment
Drug · Other
Lead sponsor
Alaa Sada
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Recruiting No phase listed Observational

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

NCT07702461
View directory record Official record
Conditions
Obesity & Overweight, Diabetes (DM)
Interventions
Glucagon-Like Peptide-1 Agonist (GLP-1)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of GLP-1 RAs on Human Lactation Outcomes

NCT07720414
View directory record Official record
Conditions
Lactation, Weight Loss
Interventions
Injected GLP-1 Receptor Agonists and Dual Agonists
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Recruiting Phase 4 Interventional

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

NCT07257484
View directory record Official record
Conditions
Obesity (Disorder), Breast Cancer
Interventions
Tirzepatide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

NCT06662383
View directory record Official record
Conditions
Obesity
Interventions
Retatrutide, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
40
States / cities
Tempe, Arizona • Newport Beach, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Enrolling by invitation Phase 4 Interventional

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

NCT07057310
View directory record Official record
Conditions
Obesity, Menopause
Interventions
semaglutide or tirzepatide, Lifestyle modification intervention
Drug · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Recruiting Phase 2 Interventional

Multi-Site Trial of Tirzepatide for Smoking Cessation

NCT07602699
View directory record Official record
Conditions
Smoking Cessation, Smoking Behaviors
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
21 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

NCT06737042
View directory record Official record
Conditions
Obesity and Overweight
Interventions
GZR18, Tirzepatide
Drug
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Bessemer, Alabama • Centreville, Alabama • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Recruiting Phase 1 Interventional

Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

NCT06575738
View directory record Official record
Conditions
Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
Interventions
Injectable semaglutide or injectable tirzepatide, Standard postoperative care
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 24 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Active, not recruiting No phase listed Observational

Comparison of Body Composition Changes With Weight Loss Interventions

NCT07115069
View directory record Official record
Conditions
Obesity
Interventions
GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic)
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 19, 2026, 7:09 PM EDT
Not yet recruiting Not applicable Interventional

High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)

NCT07700030
View directory record Official record
Conditions
Weight Loss
Interventions
High protein diet, Resistance Training (RT) Programs
Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
30 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 19, 2026, 7:09 PM EDT

About this Tirzepatide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Tirzepatide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Tirzepatide.